Castle Biosciences, Inc. Stock News

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle will release its financial results for the second quarter and six months ended June 30, 2023, after the close of market on Aug. 2, 2023.

Castle's CEO and board chairman each unloaded significant amounts of company stock. The company focuses on medical diagnostic tests, primarily to inform cancer treatment choices.

Castle Biosciences, Inc shares surged 55% to $20.64 on Friday after Novitas, a regional Medicare administrative contractor, reversed its draft policy that would have denied coverage of Castle's Decis

Novitas is withdrawing a draft policy that would have denied coverage for Castle's cancer tests. It must still wait on a new draft policy from the regional Medicare administrative contractor.

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle will present new data on DecisionDx®-SCC and DecisionDx®-Melanoma at AHNS' 11th International Conference on Head and Neck Cancer.

A Medicare contractor proposed non-coverage of one of Castle's skin cancer tests. The company reiterated guidance.

Castle Biosciences' shares are down more than 3% this year. The company specializes in medical diagnostics to improve patient treatment plans.

Castle Biosciences, Inc. (NASDAQ:CSTL ) Q1 2023 Earnings Conference Call May 3, 2023 4:30 PM ET Company Participants Camilla Zuckero - Vice President, Investor Relations & Corporate Affairs Derek Maet

For investors that have the patience to ride out volatility in exchange for possible long-term upside, value stocks to buy that are discounted against book value may offer considerable intrigue. On pa

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle will present a company overview at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum on March 22 at 2:15 p.m. Easte

Castle Biosciences, Inc. (NASDAQ:CSTL ) Q4 2022 Earnings Conference Call February 28, 2023 4:30 PM ET Company Participants Camilla Zuckero - Vice President, Investor Relations and Corporate Affairs De

Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of 14.29% and 4.96%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the st

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle will release its financial results for the fourth quarter and year ended Dec. 31, 2022, after the close of market on Tuesday, Feb. 28, 2023.

Castle Biosciences has niche exposure to skin cancer, offering uncorrelated alpha potential. The stock is beaten down, with a chance to re-rate to the upside.

Castle Biosciences, Inc. (NASDAQ:CSTL ) Q3 2022 Earnings Conference Call November 2, 2022 4:30 PM ET Company Participants Camilla Zuckero - Vice President, Investor Relations and Corporate Affairs Der